Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)
TipRanks (Tue, 22-Sep 6:10 AM ET)
Invivyd to Participate in Upcoming September Investor Conferences
Globe Newswire (Tue, 8-Sep 7:01 AM ET)
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 3-Sep 7:01 AM ET)
Globe Newswire (Tue, 1-Sep 7:01 AM ET)
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire (Thu, 13-Aug 4:05 PM ET)
Globe Newswire (Mon, 6-Jul 7:01 AM ET)
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
Globe Newswire (Mon, 29-Jun 7:00 AM ET)
Market Chameleon (Thu, 9-Apr 7:44 AM ET)
IVVD Secures FDA Clearance for COVID Antibody Trials, Paving Way for Novel Prevention Approach
Market Chameleon (Mon, 6-Oct 7:23 AM ET)
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
Invivyd trades on the NASDAQ stock market under the symbol IVVD.
As of September 24, 2026, IVVD stock price declined to $0.91 with 3,655,873 million shares trading.
IVVD has a beta of 1.14, meaning it tends to be more sensitive to market movements. IVVD has a correlation of 0.01 to the broad based SPY ETF.
IVVD has a market cap of $268.09 million. This is considered a Small Cap stock.
Last quarter Invivyd reported $14 million in Revenue and -$.14 earnings per share. This fell short of revenue expectation by $-536,064 and met earnings estimates .
In the last 3 years, IVVD traded as high as $5.20 and as low as $.35.
The top ETF exchange traded funds that IVVD belongs to (by Net Assets): VTI, VXF, VTWO, BBC, PRFZ.
IVVD has underperformed the market in the last year with a return of -21.6%, while the SPY ETF gained +16.8%. In the last 3 month period, IVVD fell short of the market, returning -2.6%, while SPY returned +4.8%. However, in the most recent 2 weeks IVVD has outperformed the stock market by returning +14.1%, while SPY returned +0.8%.
IVVD support price is $.86 and resistance is $.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IVVD shares will trade within this expected range on the day.